TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clear or almost clear of AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absent or mild pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: absorption efficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients on concurrent therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intention to reduce consumption
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: motor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological recovery (IES and SF-36 MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mortality during the coronary unit stay
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in uric acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk for ESKD
Endpoint domain: Mortality/survival
Primary endpoint: Kidney function decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence rate of adverse events requiring dose reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated non-incidence rate of PJP
Endpoint domain: Mortality/survival
Primary endpoint: aBMD in hip structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of ALT >2× ULN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: plasma brain natriuretic peptide level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall mean scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean arterial pressure elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate-pressure product elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T-cell apoptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CSOM cure rate
Endpoint domain: Mortality/survival
Primary endpoint: Probability of being disease free at five years
Endpoint domain: Mortality/survival
Primary endpoint: Complete-response probability estimates
Endpoint domain: Mortality/survival
Primary endpoint: Mean speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS drug effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of adenoid and/or tonsillar hypertrophy ≥25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in fast dorsiflexion angle (Tardieu R1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of painful episodes associated with casting
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of procaine penicillin compared to cefuroxime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of procaine penicillin compared to cefuroxime
Endpoint domain: Adverse events/effects
Primary endpoint: sHLA‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of surgical site infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Apical transportation or canal aberration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleepiness
Endpoint domain: Adverse events/effects
Primary endpoint: Sponsorship at the end of treatment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Abstinence from stimulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No drug-related problems at follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: improvement in emotion recognition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in expressive reluctance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SvO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2* time-course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cholesterol to high-density lipoprotein ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abdominal fat reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: interference with sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: median number of days without rescue medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median IPSS decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median QoL decrease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative sore throat (POST) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of postoperative sore throat (POST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean final IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: requirement for glaucoma medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in allodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASMT response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global change in anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: respiratory compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean concentrations of serum total, esterified and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in glucose excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical improvement in DBD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic encephalopathy episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Full recovery
Endpoint domain: Mortality/survival
Primary endpoint: Sustained remission
Endpoint domain: Mortality/survival
Primary endpoint: PCS affective symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue oxycodone demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early post-operative mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-body treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face/neck treatment success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aminotransferase normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis C virus RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of food insecurity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: abdominal subcutaneous fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DeMeester score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LESP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative dysphagia
Endpoint domain: Adverse events/effects
Primary endpoint: 24-h urinary phosphate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of early postoperative cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: first ray motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of distribution of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardioacceleratory effects of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Epinephrine-releasing effects of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Testing recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: TMS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Water swallow score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallow dysfunction score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kaplan-Meier survivorship with revision as the end point
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of physical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARMS patency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilator-associated pneumonia (VAP) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: median nasal score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: threshold dose in skin prick tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thiopurine discontinuation rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Width of keratinized tissue (WKT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative liver function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: miscarriage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Proliferation rate to PHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of CD45RO+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine response (IL-2 and TNF-alpha levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: death and CHF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Coronary arterial dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median SRT improvement in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in mean acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acne scar improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dead space ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum uric acid (s-UA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Death or cardiovascular complications during hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Change in apnea-hypopnea index (ΔAHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Salivary S. mutans levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global health status scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction score with Nd:YAG laser
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak plasma epinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort (visual analog scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caffeine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ventricular rate reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Parent ADHD Rating Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Teacher ADHD Rating Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical and radiographical state of patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with overdentures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrepancy between perceived muscularity and ideal muscularity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of LFCN block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection sensitivity of focal hepatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and tissue levels of malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic cure rates at treatment day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-stent intimal hyperplasia volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete protection from acute emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discriminatory power of intubation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percent change in normalized total atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total systemic exposure (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of stunting among boys aged 0-54 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hsCRP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Intensity Difference (PID) at 10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean 1-hour CCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to next transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Encopresis frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of patients losing > 10% of initial body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapidity of repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of severe hazelnut allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective symptoms to hazelnut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: use of stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of Lp(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of early adverse ischemic events
Endpoint domain: Adverse events/effects
Primary endpoint: composite morbidity and mortality endpoint
Endpoint domain: Mortality/survival
Primary endpoint: airway stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep hours
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Achieved SVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving antiviral therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central subfield thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROC-AUC for HbA(1c) in predicting diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: movement preparation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma clot permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinolysis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean diurnal variation in PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean nocturnal void volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean time to first nocturnal void
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prolongation of absolute refractory periods (aRPs and aRPf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lumen volume index (VI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 10-year disease specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 15-year disease specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in office diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in office systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in home diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time saved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to remission
Endpoint domain: Mortality/survival
Primary endpoint: Rate of patients experiencing PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for indomethacin for intolerable pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: combined risk of death or hospitalization for cardiovascular reason
Endpoint domain: Mortality/survival
Primary endpoint: combined risk of death or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: days spent in the hospital for heart failure
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pregnancy rate per initiated cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Retail availability of tobacco
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean general health score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median serum anti‐TPO antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Agitation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-time success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effective airway time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment efficacy rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of amisulpride-ECT combination
Endpoint domain: Adverse events/effects
Primary endpoint: Cost-effectiveness of the RTW program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stroke index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceleration index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain control ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased effort during driving test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increased sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced alertness
Endpoint domain: Adverse events/effects
Primary endpoint: minutes per week being physically active
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abdominal strength and endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower body strength and endurance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower body flexibility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic agility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterialized bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes